Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s latest generic exclusivity dilemma is Merck’s Cosopt

Executive Summary

FDA is soliciting comments on how to handle approval of generics for Merck's Cosopt (dorzolamide/timolol ophthalmic solution). The product's pediatric exclusivity expires Oct. 28, and both Hi Tech and Apotex have tentatively approved ANDAs. There are two complications, FDA notes in its 1request for comment: "at least one applicant became eligible for 180-day exclusivity" by virtue of a Paragraph IV certification on Oct. 11, 2005, but more than 30 months have elapsed since then, seeming to pull one part of the trigger that would force the applicant to forfeit exclusivity. Also, Merck has requested delisting of the product's other patents, which expire in 2011, a move that could pull the part of the forfeiture trigger regarding "failure to market relating to the withdrawal of patent information." Comments on the docket (FDA-2008-N-0483) are due Sept. 19

You may also be interested in...



Warning Letter Roundup & Recap – 10 December 2019

No device-related warning letters were released by the US FDA the week of 10 December.

Immuno-Oncology Continues To Draw Pharma Companies To The Deal Table

Immuno-oncology development trends are revealed through an analysis of deals between cancer drug developers over the past five years.

What’s Next After 20 Years Of NICE?

Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.

UsernamePublicRestriction

Register

PS050068

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel